Navigation Links
Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/11/2009

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Tuesday, November 17 at 4:10 p.m. EST. A breakout session will follow Dr. Orndorff's presentation where he will be available for questions and answers.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.

For more information about Accera, please visit www.accerapharma.com.

    Contacts:
    Accera, Inc.
    Steve Orndorff, Ph.D.
    President and CEO
    sorndorff@accerapharma.com

    Tiberend Strategic Advisors, Inc.
    (212) 827-0020
    Andrew Mielach
    amielach@tiberendstrategicadvisors.com

    or

    Farrell Denby
    fdenby@tiberendstrategicadvisors.com

SOURCE Accera, Inc.


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
2. CryoLife to Present at Upcoming Investor Conferences in New York
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
5. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. VIVUS to Present at Lazard Capital Markets Healthcare Conference
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Thoratec Presentation at Canaccord Adams Conference to be Webcast
9. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
10. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
11. Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/23/2017)...  Leaf Healthcare, recognized for developing one of ... ulcer prevention, will unveil its comprehensive mobility monitoring ... Nurses, National Teaching Institute and Critical Care Exposition ... Patient Monitoring System is the first mobility monitoring ... system seamlessly tracks patient movement throughout the mobility ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or ... But how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional ... early symptoms of AMD? A study published recently in Dove Medical Press ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when it ... it, and some people don't like it at all. FindaTopDoc took a look at ... Erotic literature can give readers a taste of their deepest, darkest fantasies and has ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Private Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update ... the United States. In 2012, the Biggert-Waters Act was enacted to reflect the ...
Breaking Medicine News(10 mins):